MRNA

Moderna (MRNA) Stock Analysis

Research Moderna (MRNA) with company financials, earnings context, valuation indicators, risk analysis and related market news.

Research record updated: . Individual measures may refer to different reporting periods.

Ticker
MRNA
Company
Moderna
Sector
Healthcare
Industry
Biotechnology
Market cap
$74.84B
Financial data source
FMP financial statements + FMP cash flow statements + FMP balance sheet + income statements
Annual revenue (reporting year not supplied)
$1.94B
Annual net income (reporting year not supplied)
$-2.82B
Annual free cash flow (reporting year not supplied)
$-2.06B
Trailing revenue
$2.23B
Trailing net income
$-3.15B
Total assets
$12.34B
Total liabilities
$3.69B

Moderna (MRNA) Stock Analysis research

Moderna, Inc. develops messenger-RNA medicines and vaccines, with commercial products led by Spikevax for COVID-19 and mRESVIA for respiratory syncytial virus, alongside a broad pipeline in influenza, cancer, rare diseases, and latent viruses. Recent investor coverage has emphasized its cost-reduction program, uneven vaccine demand, regulatory progress for newer products, and the need to replace declining COVID revenue with durable launches. Its next-generation COVID vaccine, mNEXSPIKE, is important because it is designed to produce strong protection with a smaller dose and potentially improve manufacturing efficiency. Moderna is also developing personalized cancer vaccines that use tumor-specific genetic information to train the immune system, a potential game changer if late-stage trials confirm meaningful survival benefits. Combination respiratory vaccines and vaccines against influenza, norovirus, and cytomegalovirus could broaden revenue, but most remain commercially unproven. Overall sentiment is highly speculative: the pipeline offers major upside, while near-term execution and shrinking pandemic sales remain serious concerns. Within Healthcare, Moderna has stronger technological differentiation and faster potential growth than many mature pharmaceutical companies, but its roughly seventy-billion-dollar valuation is demanding relative to current sales and losses; the broader market generally offers more predictable earnings. I rate the stock 5/10 in Healthcare: its scientific strength supports strategic value, but its sector-based valuation appears expensive unless pipeline products generate substantial future cash flow. The share-price momentum is exceptionally strong and risk-adjusted performance has been favorable, yet the extreme volatility means recent gains may reverse quickly. The business remains loss-making, consumes cash, has negative operating returns, and depends on financing, successful trials, regulatory approvals, and renewed vaccine demand; the future could improve sharply, but the downside is substantial if those conditions fail. Bearish.

Review the available company profile, financial history, valuation context and investor signals for Moderna. Compare the reported operating results with the valuation and risk measures below.

The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.